肿瘤中Raf激酶抑制蛋白下调机制

doi:10.3760/cma.j.issn.1673-422X.2015.10.008

摘要/Abstract

摘要： Raf激酶抑制蛋白（RKIP）已被证实在多条蛋白激酶信号通路的调节中发挥重要作用，与肿瘤关系密切。研究表明其在肿瘤中表达下调，机制涉及多方面，包括遗传调控和甲基化、乙酰化、组蛋白修饰、微小RNA调节等表观遗传学调控，并与Snail、NFκB等蛋白形成环路调节。

关键词: 磷脂酰乙醇胺结合蛋白质, 肿瘤, 基因表达调控

Abstract: Raf -kinase inhibiting protein (RKIP) plays a vital role in various physiological processes and participates in multiple signaling pathways, with a close releationgship with tumor. The mechanism of RKIP down-regulation in neoplasms includes transcriptional regulation, methylation, acetylation, histone modification, microRNA regulation and NF-κB/Snail/RKIP loop regulation.

Key words: Phosphatidylethanolamine binding protein, Neoplasms, Gene expression regulation

王韵, 李宇红. 肿瘤中Raf激酶抑制蛋白下调机制[J]. 国际肿瘤学杂志, 2015, 42(10): 750-752.

Wang Yun, Li Yuhong. Mechanism of Raf kinase inhibitor protein down-regulation in cancer[J]. Journal of International Oncology, 2015, 42(10): 750-752.

参考文献

［1］ Al-Mulla F, Bitar MS, Taqi Z, et al. RKIP: much more than Raf kinase inhibitory protein［J］. J Cell Physiol, 2013, 228(8): 1688-1702. ［2］王越. Raf激酶抑制蛋白与恶性肿瘤［J］. 国际肿瘤学杂志, 2007, 34(1): 5-8. ［3］ Ren G, Baritaki S, Marathe H, et al. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer［J］. Cancer Res, 2012, 72(12): 3091-3104. ［4］ Zhang B, Wang O, Qin J, et al. cisacting elements and transacting factors in the transcriptional regulation of raf kinase inhibitory protein expression［J］. PLoS One, 2013, 8(12): e83097. ［5］ Beach S, Tang H, Park S, et al. Snail is a repressor of RKIP transcription in metastatic prostate cancer cells［J］. Oncogene, 2008, 27(15): 2243-2248. ［6］ Guo W, Dong Z, Lin X, et al. Decreased expression and aberrant methylation of Raf kinase inhibitory protein gene in esophageal squamous cell carcinoma［J］. Cancer Invest, 2012, 30(10): 703-711. ［7］ AlMulla F, Hagan S, AlAli W, et al. Raf kinase inhibitor protein: mechanism of loss of expression and association with genomic instability［J］. J Clin Pathol, 2008, 61(4): 524-529. ［8］ Zlobec I, Bihl M, Foerster A, et al. Comprehensive analysis of CpG island methylator phenotype (CIMP)high, low, and negative colorectal cancers based on protein marker expression and molecular features［J］. J Pathol, 2011, 225(3): 336-343. ［9］ Doyle B, Hagan S, AlMulla F, et al. Raf kinase inhibitor protein expression combined with peritoneal involvement and lymphovascular invasion predicts prognosis in Dukes′ B colorectal cancer patients［J］. Histopathology, 2013, 62(3): 505-510. ［10］ Minoo P, Zlobec I, Baker K, et al. Loss of raf1 kinase inhibitor protein expression is associated with tumor progression and metastasis in colorectal cancer［J］. Am J Clin Pathol, 2007, 127(5): 820-827. ［11］ Martinho O, Gouveia A, Silva P, et al. Loss of RKIP expression is associated with poor survival in GISTs［J］. Virchows Arch, 2009, 455(3): 277-284. ［12］ Minoo P, Baker K, Goswami R, et al. Extensive DNA methylation in normal colorectal mucosa in hyperplastic polyposis［J］. Gut, 2006, 55(10): 1467-1474. ［13］ Huang L, Dai T, Lin X, et al. MicroRNA-224 targets RKIP to control cell invasion and expression of metastasis genes in human breast cancer cells［J］. Biochem Biophys Res Commun, 2012, 425(2): 127-133. ［14］ Poma P, Labbozzetta M, Vivona N, et al. Analysis of possible mechanisms accounting for raf1 kinase inhibitor protein downregulation in hepatocellular carcinoma［J］. OMICS, 2012, 16(11): 579-588. ［15］ Li J, Wang Y, Song Y, et al. miR27a regulates cisplatin resistance and metastasis by targeting RKIP in human lung adenocarcinoma cells［J］. Mol Cancer, 2014, 13: 193. ［16］ Selbach M, Schwanhusser B, Thierfelder N, et al. Widespread changes in protein synthesis induced by microRNAs［J］. Nature, 2008, 455(7209): 58-63. ［17］ Schwanhusser B, Gossen M, Dittmar G, et al. Global analysis of cellular protein translation by pulsed SILAC［J］. Proteomics, 2009, 9(1): 205-209. ［18］ Burns KE, Darwin KH. Pupylation versus ubiquitylation: tagging for proteasomedependent degradation［J］. Cell Microbiol, 2010, 12(4): 424-431. ［19］ Emanuele MJ, Elia AE, Xu Q, et al. Global identification of modular cullinRING ligase substrates［J］. Cell, 2011, 147(2): 459-474. ［20］ Kim W, Bennett EJ, Huttlin EL, et al. Systematic and quantitative assessment of the ubiquitinmodified proteome［J］. Mol Cell, 2011, 44(2): 325-340. ［21］ Mandili G, Khadjavi A, Gallo V, et al. Characterization of the protein ubiquitination response induced by Doxorubicin［J］. FEBS J, 2012, 279(12): 2182-2191. ［22］ Guil S, Esteller M. DNA methylomes, histone codes and miRNAs: tying it all together［J］. Int J Biochem Cell Biol, 2009, 41(1): 87-95. ［23］ Bernstein BE, Meissner A, Lander ES. The mammalian epigenome［J］. Cell, 2007, 128(4): 669-681. ［24］ Cano A, PérezMoreno MA, Rodrigo I, et al. The transcription factor snail controls epithelialmesenchymal transitions by repressing Ecadherin expression［J］. Nat Cell Biol, 2000, 2(2): 76-83. ［25］ Baritaki S, HuertaYepez S, Sahakyan A, et al. Mechanisms of nitric oxidemediated inhibition of EMT in cancer: inhibition of the metastasisinducer Snail and induction of the metastasissuppressor RKIP［J］. Cell Cycle, 2010, 9(24): 4931-4940. ［26］ Yook JI, Li XY, Ota I, et al. Wntdependent regulation of the Ecadherin repressor snail［J］. J Biol Chem, 2005, 280(12): 11740-11748. ［27］ Baritaki S, Yeung K, Palladino M, et al. Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI0052 in tumor cell chemoimmunosensitization［J］. Cancer Res, 2009, 69(21): 8376-8385. ［28］ Bonavida B, Baritaki S. The novel role of Yin Yang 1 in the regulation of epithelial to mesenchymal transition in cancer via the dysregulated NFkappaB/Snail/YY1/RKIP/PTEN Circuitry［J］. Crit Rev Oncog, 2011, 16(34): 211-226. ［29］ Baritaki S, Bonavida B. Viral infection and cancer: the NFkappaB/Snail/RKIP loop regulates target cell sensitivity to apoptosis by cytotoxic lymphocytes［J］. Crit Rev Immunol, 2010, 30(1): 31-46.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.